iSAM Funds UK Ltd Trims Stock Position in STERIS plc $STE

iSAM Funds UK Ltd trimmed its stake in shares of STERIS plc (NYSE:STE) by 35.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,466 shares of the medical equipment provider’s stock after selling 2,967 shares during the quarter. iSAM Funds UK Ltd’s holdings in STERIS were worth $1,353,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of STE. Vanguard Group Inc. raised its stake in shares of STERIS by 0.4% during the third quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider’s stock worth $3,022,114,000 after purchasing an additional 50,393 shares during the last quarter. State Street Corp grew its position in STERIS by 2.4% in the 2nd quarter. State Street Corp now owns 4,188,103 shares of the medical equipment provider’s stock valued at $1,006,069,000 after buying an additional 98,220 shares during the last quarter. Geode Capital Management LLC increased its stake in STERIS by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider’s stock valued at $592,980,000 after buying an additional 46,859 shares during the period. Orbis Allan Gray Ltd increased its stake in STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after buying an additional 556,088 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in STERIS by 16.4% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock worth $387,797,000 after buying an additional 221,199 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

STE has been the subject of several recent analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and an average price target of $275.20.

STERIS Trading Up 1.1%

Shares of STE stock opened at $214.66 on Friday. The business’s fifty day moving average price is $250.96 and its 200 day moving average price is $250.50. The firm has a market capitalization of $21.05 billion, a PE ratio of 29.94 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. STERIS plc has a 1-year low of $204.90 and a 1-year high of $269.44.

STERIS (NYSE:STE) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, sell-side analysts forecast that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be paid a $0.63 dividend. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is 35.15%.

Insider Buying and Selling

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.07% of the company’s stock.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.